Background There is still no reliable biomarker for the diagnosis of pancreatic
adenocarcinoma. Carbohydrate antigen 19–9 (CA 19–9) is a tumor marker only …

Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer (PC)
with a 5-year survival rate of only about 10% in the United States. Early diagnosis will …

Objective Current non-invasive diagnostic tests can distinguish between pancreatic cancer
(pancreatic ductal adenocarcinoma (PDAC)) and chronic pancreatitis (CP) in only about two …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer
mortality. Carbohydrate antigen 19.9 (CA19. 9), the only tumor marker available to detect …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of
reasons including very late diagnosis. This in part is due to the lack of understanding of the …

Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine
management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies …

Pancreatic cancer has the highest mortality amongst all major organ cancers. Early
detection is key to reduce deaths related to pancreatic cancer. However, early detection has …

Pancreatic adenocarcinoma accounts for nearly 90–95% of exocrine malignant tumors of
the pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA …

Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The
disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in …

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with
around 9% of patients surviving> 5 years. Asymptomatic in its initial stages, PDAC is mostly …